FDA approves more convenient form of Roche blood cancer drug

(Reuters) - U.S. health regulators on Thursday approved a new formulation of Roche's big-selling cancer drug Rituxan for three common types of blood cancers that allows for relatively quick administration via injection under the skin in place of a lengthy intravenous infusion, the company said.